Advertisement
Table 1 Retrospective studies in which patients with advanced ovarian cancer were treated with neoadjuvant chemotherapy followed by cytoreductive surgery.
| Authors | No. of patients treated with neoadjuvant chemotherapy | Main conclusion |
|---|---|---|
| Kuhn W et al. (8) | 37 | Better median survival in the group treated with neoadjuvant chemotherapy compared with the group treated with primary cytoreductive surgery |
| Onnis A et al. (9) | 88 | In 46% of operated patients, the residual tumour was < 2 cm. An improvement in the quality of surgery and disease-free period was observed, while survival rate did not improve when comparing the neoadjuvant chemotherapy group to the group that received adjuvant chemotherapy |
| Shimizu Y et al. (10) | 74 | In 46% of operated patients, the residual tumour was < 2 cm. Survival for the optimally debulked neoadjuvant chemotherapy group was significantly higher than that for the optimally debulked adjuvant chemotherapy group |
| Vergote I et al. (11) | 75 | Crude survival was higher when selecting about one-half of patients for neoadjuvant chemotherapy |
| Surwit E. et al. (12) | 29 | Median survival was 22 months |
| Schwartz PE et al. (13) | 59 | No statistical difference was observed in overall and progression-free survival between the group treated with neoadjuvant chemotherapy and the conventionally treated group |
| Jacob JH et al. (14) | 22 | The same survival as in 18 matched controls |
| Lim JT et al. (15) | 30 | Neoadjuvant chemotherapy can make patients operable |
| Lawton FG et al. (16) | 36 | 78% of patients were treated with neoadjuvant chemotherapy, of whom in 89% the residual tumour was < 2 cm |
| Ansquer Y et al. (17) | 54 | Better survival of patients treated with neoadjuvant chemotherapy compared to patients with non-debulked tumours |
| Recchia F et al. (18) | 34 | Median survival was 28 months for stage IV patients |
| Loizzi V et al. (19) | 30 | Survival in the neoadjuvant and adjuvant chemotherapy groups was similar |
| Kayikcioglu F et al. (20) | 45 | Primary neoadjuvant chemotherapy followed by cytoreductive surgery did not appear to worsen the prognosis |
| Morice P et al. (21) | 57 | Survival rates were similar in patients who underwent interval debulking surgery or primary debulking surgery |
| Ivanov S et al. (22) | 46 | The five-year survival rate following the neoadjuvant chemotherapy was the same as in case of conventional chemotherapy |
